The board of directors of Recursion, a Salt Lake City-based clinical-stage company pioneering AI-enabled drug discovery and development, has appointed Fred Hassan as chair. Hassan’s experience includes more than four decades in the pharmaceutical industry. He has grown global businesses and led teams that brought multiple medicines through development, regulatory approval and commercial launch. Hassan served as chair and chief executive officer of Schering-Plough Corp., chair and CEO of Pharmacia Corp, and held executive and leadership positions with Wyeth and Sandoz Pharmaceuticals (now Novartis). Hassan serves as lead independent director of BridgeBio Pharma and is executive chair of Norstella. Hassan’s current public board memberships include Precigen and BridgeBio Pharma. His previous boards included Prometheus Biosciences, Amgen, Time Warner, Avon and Bausch & Lomb. Hassan also brings experience as an investor. He is a director and was a partner and managing director at Warburg Pincus. Hassan also has chaired the Pharmaceutical Research and Manufacturers of America and the International Federation of Pharmaceutical Manufacturers & Associations, and he co-founded the CEO Forum with Accenture to bring together chief executives from across the life sciences.

Keep reading SLBJ


